NeuropsychBrainAge: a biomarker for conversion from mild cognitive impairment to Alzheimer’s disease

Jorge Garcia Condado, Jesus M. Cortes, Alzheimer’s Disease Neuroimaging Initiative
doi: https://doi.org/10.1101/2022.11.29.22282870

Article Information

doi 
https://doi.org/10.1101/2022.11.29.22282870
History 
  • November 29, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Jorge Garcia Condadoa,b,*,
  2. Jesus M. Cortesa,c,d,*,
  3. Alzheimer’s Disease Neuroimaging Initiative1
  1. aBiocruces-Bizkaia Health Research Institute, Barakaldo, Spain
  2. bBiomedical Research Doctorate Program, University of the Basque Country, Leioa, Spain
  3. cDepartment of Cell Biology and Histology, University of the Basque Country, Leioa, Spain
  4. dIKERBASQUE Basque Foundation for Science, Bilbao, Spain
  1. ↵*Corresponding author at: Computational Neuroimaging Laboratory, Biocruces-Bizkaia Health Research Institute, Plaza Cruces S/N, 48903 Barakaldo, Bizkaia, Spain Email address: jorge.garciacondado{at}osakidetza.eus (J. Garcia Condado), jesus.m.cortes{at}gmail.com (J.M. Cortes)
Back to top
Posted November 29, 2022.
Download PDF
Data/Code
Email
NeuropsychBrainAge: a biomarker for conversion from mild cognitive impairment to Alzheimer’s disease
Jorge Garcia Condado, Jesus M. Cortes, Alzheimer’s Disease Neuroimaging Initiative
medRxiv 2022.11.29.22282870; doi: https://doi.org/10.1101/2022.11.29.22282870
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area